Medicine guide
Trixeo Aerosphere
·
- Prescription status not stated
- Breathing, airways, allergies and cough
- Active substance
- Formoterol;glycopyrronium bromide;budesonide
- Made by
- AstraZeneca AB
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Trixeo Aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | AstraZeneca AB |
|---|---|
| Active substance | Formoterol;glycopyrronium bromide;budesonide |
| Used in | Breathing, airways, allergies and cough |
| Classification | R03AL · Breathing, airways, allergies and cough |
| Authorised on | 2020-12-09 |
| Last updated by the regulator | 2025-09-19 |
| EMA product number | EMEA/H/C/004983 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).